Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience

Leuk Lymphoma. 2017 Nov;58(11):2624-2632. doi: 10.1080/10428194.2017.1312376. Epub 2017 May 9.

Abstract

Here, we describe our experience with secondary neurolymphomatosis (NL) in non-Hodgkin lymphoma patients, with the emphasis on the diagnosis process. A retrospective chart review of 12 patients from 3 tertiary academic centers between January 2005 and December 2015 was conducted. Secondary NL was diagnosed within a median interval of 10 months (range 5-41 months) after initial diagnosis of NHL. Painful neuropathy was present in 66.7%, but the diagnosis of NL was delayed in nine out of 12 patients (75.0%) by median of 2 months. Diagnostic modalities included CSF analysis performed in nine patients (75.0%), electrodiagnostic studies in seven (58.3%), radiologic studies in all, and nerve biopsy in two (16.7%). The diagnostic yield was 100.0% (15/15) for FDG-PET/CT and 75.0% (9/12) for MRI. Our experience emphasizes the importance of clinical suspicion of NL in patients with previous history of NHL and selection of diagnostic modality with the greatest clinical utility.

Keywords: FDG-PET/CT; MRI; Neurolymphomatosis; non-Hodgkin lymphoma.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Lymphoma, Non-Hodgkin / diagnostic imaging
  • Lymphoma, Non-Hodgkin / pathology*
  • Magnetic Resonance Imaging / methods
  • Male
  • Middle Aged
  • Peripheral Nervous System Neoplasms / diagnosis*
  • Peripheral Nervous System Neoplasms / diagnostic imaging
  • Peripheral Nervous System Neoplasms / secondary*
  • Positron Emission Tomography Computed Tomography / methods
  • Retrospective Studies
  • Tertiary Care Centers*

Substances

  • Fluorodeoxyglucose F18